

11. Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. *J Pediatr* 1982; 101:514.
12. Broyer, M, Meyrier, A, Niaudet, P, Habib R. Minimal changes and focal and segmental glomerular sclerosis. In: Oxford Textbook of Clinical Nephrology. Cameron, JS, Davison, MA, Grünfeld, JP, et al (Eds), Oxford Medical Publications, 1992, p. 298.
13. MacDonald, NE, Wolfish, N, McLaine, P, et al. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. *J Pediatr* 1986; 108:378.
14. Abeyagunawardena, AS, Trompeter, RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. *Arch Dis Child* 2008; 93:226.
15. Mattoo, TK, Mahmoud, MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. *Nephron* 2000; 85:343.
16. Cameron, JS, Chantler, C, Ogg, CS, White, RHR. Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. *Br Med J* 1974; 4:7.
17. Chiu, J, Drummond, KN. Long-term follow-up of cyclophosphamide therapy in frequent-relapsing minimal-lesion nephrotic syndrome. *J Pediatr* 1974; 84:825.
18. McDonald, J, Murphy, AV, Arneil, GC. Long-term assessment of cyclophosphamide therapy for nephrosis. *Lancet* 1974; 2:980.
19. Durkan, AM, Hodson, EM, Willis, NS, Craig, JC. Non-corticosteroid treatment for nephrotic syndrome in children. *Cochrane Database Syst Rev* 2005; :CD002290.
20. Vester, U, Kranz, B, Zimmermann, S, Hoyer, PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: Outcome and outlook. *Pediatr Nephrol* 2003; 18:661.
21. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. *N Engl J Med* 1982; 306:451.
22. Kyrieleis, HA, Levtchenko, EN, Wetzels, JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. *Am J Kidney Dis* 2007; 49:592.
23. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. *Arch Dis Child* 1987; 62:1102.
24. Ueda, N, Kuno, K, Ito, S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. *Arch Dis Child* 1990; 65:1147.
25. Donia, AF, Gazareen, SH, Ahmed, HA, et al. Pulse cyclophosphamide inadequately suppresses recurrence of minimal change nephrotic syndrome in corticoid-dependent children. *Nephrol Dial Transplant* 2003; 18:2054.
26. Prasad, N, Gulati, S, Sharma, RK, et al. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. *Pediatr Nephrol* 2004; 19:494.
27. Niaudet, P. Comparison of cyclosporine and chlorambucil in the treatment of idiopathic nephrotic syndrome: A multicenter randomized controlled trial. The French Society of Pediatric Nephrology. *Pediatr Nephrol* 1992; 6:1.
28. Niaudet, P, Habib, R. Cyclosporine in the treatment of idiopathic nephrosis. *J Am Soc Nephrol* 1994; 5:1049.
29. Niaudet, P, Broyer, M, Habib, R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. *Clin Nephrol* 1991; 35 Suppl 1:S31.
30. Tejani, AT, Butt, K, Trachtman, H, et al. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. *Kidney Int* 1988; 33:729.
31. Kano, K, Kyo, K, Yamada, Y, et al. Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low dose cyclosporine-A for 2 years for steroid-dependent nephrotic syndrome. *Clin Nephrol* 1999; 52:19.
32. Mahmoud, I, Basuni, F, Sabry, A, et al. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 2005; 20:735.
33. Habib, R, Niaudet, P. Comparison between pretreatment and posttreatment renal biopsies in children receiving cyclosporine for idiopathic nephrosis. *Clin Nephrol* 1994; 42:141.
34. Hirano T, Kawamura T, Fukuda S, Kohsaka S, Yoshikawa N, Yoshida M et al. Implication of cholesterol in cyclosporine pharmacodynamics in minimal change nephrotic syndrome. *Clin Pharmacol Ther* 2003;74(6):581-590.
35. Ingulli E, Tejani A. Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome. *J Am Soc Nephrol* 1992;3(2):254-259.
36. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. *Kidney Int* 2008;73(10):1167-1173.
37. Bagga, A, Hari, P, Moudgil, A, Jordan, SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. *Am J Kidney Dis* 2003; 42:1114.
38. Novak, I, Frank, R, Vento, S, et al. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. *Pediatr Nephrol* 2005; 20:1265.
39. Hogg, RJ, Fitzgibbons, L, Bruick, J, et al. Mycophenolate Mofetil in Children with Frequently Relapsing Nephrotic Syndrome: A Report from the Southwest Pediatric Nephrology Study Group. *Cin J Am Soc Nephrol* 2006; 1:1173.
40. Fujinaga, S, Ohtomo, Y, Umino, D, et al. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. *Pediatr Nephrol* 2007; 22:71.
41. Afzal, K, Bagga, A, Menon, S, et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. *Pediatr Nephrol* 2007; 22:2059.
42. Ruth, EM, Kemper, MJ, Leumann, EP, et al. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. *J Pediatr* 2005; 147:202.
43. Dorresteijn, EM, Kist-van Holthe, JE, Levtchenko, EN, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. *Pediatr Nephrol* 2008; 23:2013.
44. Guignon, V, Dallochio, A, Baudouin, V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. *Pediatr Nephrol* 2008; 23:1269.
45. Sellier-Leclerc, AL, Macher, MA, Loirat, C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. *Pediatr Nephrol* 2010; 25:1109.
46. Haffner, D, Fischer, DC. Nephrotic syndrome and rituximab: facts and perspectives. *Pediatr Nephrol* 2009; 24:1433.
47. Schulman, SL, Kaiser, BA, Polinsky, MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: Superiority of response to corticosteroid therapy over histopathologic patterns. *J Pediatr* 1988; 113:996.
48. Tarshish, P, Tobin, JN, Berstein, J, Edelman, CM. Cyclophosphamide does not benefit patients with focal segmental glomerular sclerosis. A report of the International Study of Kidney Disease in Children. *Pediatr Nephrol* 1996; 10:590.
49. Geary, DF, Farine, M, Thomer, P, Bauml, R. Response to cyclophosphamide in steroid resistant focal segmental glomerulosclerosis. A reappraisal. *Clin Nephrol* 1984; 22:109.
50. Niaudet, P, for the French Society of Pediatric Nephrology. Treatment of childhood steroid resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. *J Pediatr* 1994; 125:981.
51. Gregory, MJ, Smoyer, WE, Sedmanet, et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: A clinical and histologic analysis. *J Am Soc Nephrol* 1996; 7:543.
52. Ponticelli, C, Edefonti, A, Ghio, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing nephrotic syndrome: A multicenter randomized controlled trial. *Nephrol Dial Transplant* 1993; 8:1326.
53. Lieberman, KV, Tejani, A, for the New York-New Jersey Pediatric Nephrology Study Group. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant focal segmental glomerulosclerosis in children. *J Am Soc Nephrol* 1996; 7:56.
54. Ingulli, E, Singh, A, Baqi, N, et al. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. *J Am Soc Nephrol* 1995; 5:1820.
55. Chishti, AS, Sorof, JM, Brewer, ED, Kale, AS. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. *Am J Kidney Dis* 2001; 38:754.
56. Plank, C, Kalb, V, Hinkes, B, et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome: a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. *Pediatr Nephrol* 2008; 23:1483.
57. Ehrlich, JH, Geerlings, C, Zivicnjak, M, et al. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. *Nephrol Dial Transplant* 2007; 22:2183.
58. Loeffler, K, Gowrishankar, M, Yiu, V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. *Pediatr Nephrol* 2004; 19:281.
59. Bhimma, R, Adhikari, M, Asharam, K, Connolly, C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. *Am J Nephrol* 2006; 26:544.
60. Gulati, S, Prasad, N, Sharma, RK, et al. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. *Nephrol Dial Transplant* 2008; 23:910.
61. Choudhry, S, Bagga, A, Hari, P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. *Am J Kidney Dis* 2009; 53:760.
62. Mendizabal, S, Zamora, I, Berbel, O, et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. *Pediatr Nephrol* 2005; 20:914.
63. Cattran, DC, Wang, MM, Appel, G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. *Clin Nephrol* 2004; 62:405.
64. Nakayama, M, Kamei, K, Nozu, K, et al. Rituximab for refractory focal segmental glomerulosclerosis. *Pediatr Nephrol* 2008; 23:481.
65. Bagga, A, Sinha, A, Moudgil, A. Rituximab in patients with the steroid-resistant nephrotic syndrome. *N Engl J Med* 2007; 356:2751.
66. Trompeter, RS. Steroid resistant nephrotic syndrome: A review of the treatment of focal segmental glomerulosclerosis in children. In: Recent Advances in Pediatric Nephrology, Murakami, K, Kitagawa, T, Yabuta, K, Sakai, T (Eds), Excerpta Medica, Amsterdam, 1987, pp 363-371.
67. Mendoza, SA, Reznik, M, Griswold, WR, et al. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. *Pediatr Nephrol* 1990; 4:303.
68. Tune, BM, Kirpekar, R, Sibley, RF, et al. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal glomerulosclerosis: A long-term follow-up. *Clin Nephrol* 1995; 43:84.
69. Kirpekar, R, Yorgin, PD, Tune, BM, et al. Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. *Am J Kidney Dis* 2002; 39:1143.
70. Montane, B, Abitbol, C, Chandar, J, Strauss, J. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. *Pediatr Nephrol* 2003; 18:772.
71. Haws, RM, Baum, M. Efficacy of albumin and diuretic therapy in children with nephritic syndrome. *Pediatrics* 1993; 91:1142.
72. Fakhouri, F, Bocquet, N, Taupin, P, et al. Steroid-sensitive nephrotic syndrome: From childhood to adulthood. *Am J Kidney Dis* 2003; 41:550.
73. Hyams, JS, Carey, DE. Corticosteroids and growth. *J Pediatr* 1988; 113:249.
74. Polito, C, Oporto, MR, Totino, SF, et al. Normal growth of nephrotic children during long-term alternate-day prednisone therapy. *Acta Paediatr Scand* 1986; 75:245.
75. Fleisher, DS, McCrory, WW, Rapoport, M. The effects of intermittent doses of adrenocortical steroids on the statural growth of nephrotic children. *J Pediatr* 1960; 57:192.
76. Brocklebank, JT, Harcourt, RB, Meadow, SR. Corticosteroid-induced cataracts in idiopathic nephrotic syndrome. *Arch Dis Child* 1982; 57:30.
77. Ng, JS, Wong, W, Law, RW, et al. Ocular complications of paediatric patients with nephrotic syndrome. *Clin Experiment Ophthalmol* 2001; 29:239.
78. Abeyagunawardena, AS, Hindmarsh, P, Trompeter, RS. Adrenocortical suppression increases the risk of relapse in nephrotic syndrome. *Arch Dis Child* 2007; 92:585.
79. Muller, W, Brandis, M. Acute leukemia after cytotoxic treatment for nonmalignant disease in childhood. A case report and review of the literature. *Eur J Pediatr* 1981; 136:105.
80. Cameron, JS, Chantler, C, Ogg, CS, White, RHR. Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. *Br Med J* 1974; 4:7.
81. Hogg, RJ, Portman, RJ, Milliner, D, ET. Al. Evaluation and management of proteinuria and nephritic syndrome in children recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk assessment, detection and elimination (PARADE). *Pediatrics* 2000; 105:1242

TERMO DE ESCLARECIMENTO E RESPONSABILIDADE

CICLOFOSFAMIDA E CICLOSPORINA

Eu, \_\_\_\_\_ (nome do(a) paciente), declaro ter sido informado(a) claramente sobre os benefícios, riscos, contra-indicações e principais efeitos adversos relacionados ao uso do(s) medicamento(s) CICLOFOSFAMIDA E CICLOSPORINA, indicado(s) para o tratamento da SÍNDROME NEFRÓTICA EM CRIANÇAS E ADOLESCENTES.

Os termos médicos foram explicados e todas as minhas dúvidas foram resolvidas pelo médico \_\_\_\_\_ (nome do médico que prescreve).

Assim declaro que:

Fui claramente informado(a) de que o medicamento que passo a receber pode trazer as SEGUINTE MELHORIAS:

- Dos sintomas e sinais do "estado nefrótico";
- Da quantidade de proteínas na urina;
- Prevenção da insuficiência renal aguda e da insuficiência renal crônica progressiva.

Fui também claramente informado a respeito das seguintes CONTRA-INDICAÇÕES, POTENCIAIS EFEITOS ADVERSOS E RISCOS:

- não se sabe ao certo os riscos do uso da ciclosporina na gravidez; portanto, caso engravide, devo avisar imediatamente ao meu médico;

- a ciclofosfamida não deve ser usada durante a gestação pelo risco de má formação do feto.

- os efeitos adversos mais comumente relatados para os medicamentos são:

- PARA CICLOSPORINA: problemas nos rins e fígado, tremores, aumento da quantidade de pêlos no corpo, pressão alta, aumento do crescimento da gengiva, aumento do colesterol e triglicérides, formigamentos, dor no peito, batimentos rápidos do coração, convulsões, confusão, ansiedade, depressão, fraqueza, dores de cabeça, unhas e cabelos quebradiços, coceira, espinhas, náuseas, vômitos, perda de apetite, soluços, inflamação na boca, dificuldade para engolir, sangramentos, inflamação do pâncreas, prisão de ventre, desconforto abdominal, diminuição das células brancas do sangue, linfoma, calorões, aumento da quantidade de cálcio, magnésio e ácido úrico no sangue, toxicidade para os músculos, problemas respiratórios, sensibilidade aumentada a temperatura e aumento das mamas;

- PARA CICLOFOSFAMIDA: náuseas, vômitos, perda de cabelo, risco aumentado de infecções, anemia, toxicidade para medula óssea, infecções na bexiga, risco de sangramento (redução do número de plaquetas);

- medicamentos estão contra-indicados em casos de hipersensibilidade (alergia) aos fármacos;

- o risco da ocorrência de efeitos adversos aumenta com a superdosagem.